More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$5.06B
EPS
3.01
P/E ratio
22.5
Price to sales
2.86
Dividend yield
--
Beta
0.912344
Previous close
$92.44
Today's open
$92.73
Day's range
$91.63 - $93.64
52 week range
$52.37 - $99.38
show more
CEO
Vladimir Makatsaria
Employees
3300
Headquarters
Gloucester,
Exchange
Nasdaq Global Select
Shares outstanding
55086809
Issue type
Common Stock
Healthcare
Medical Equipment & Supplies
LivaNova: Paying Off The Last Legacy Bill Just As The Sleep Apnea Market Opens Up
LivaNova PLC is rapidly transitioning into a 'clean compounder' with strong growth prospects and legacy liabilities nearly resolved. LIVN raised 2026 guidance to 9-10% revenue growth and 14% adjusted EPS growth, driven by cardiopulmonary and neuromodulation segments. Oxygenator demand exceeds supply, with LIVN gaining market share and expanding production capacity, while OSA entry is poised for favorable reimbursement tailwinds.
Seeking Alpha • Nov 12, 2026

LivaNova PLC (LIVN) Presents at 2026 UBS Global Healthcare Conference Transcript
LivaNova PLC ( LIVN ) 2026 UBS Global Healthcare Conference November 9, 2026 11:00 AM EST Company Participants Alex Shvartsburg - Chief Financial Officer Philip Kowalczyk - Chief Strategy & Corporate Development Officer Conference Call Participants Benjamin Bible Presentation Benjamin Bible Welcome. With me today is Alex Shvartsburg and Philip Kowalczyk, CFO and Head of Strategy and EVP from LivaNova.
Seeking Alpha • Nov 9, 2026

LivaNova Q3 Earnings Call Highlights
LivaNova NASDAQ: LIVN reported third-quarter 2026 revenue growth of 10% from the prior-year period, driven by double-digit gains in its Cardiopulmonary and epilepsy businesses. The medical technology company raised its full-year revenue and adjusted earnings outlook, citing commercial execution, healthy demand and progress in manufacturing capacity expansion.
MarketBeat • Nov 4, 2026

LivaNova PLC (LIVN) Q3 2026 Earnings Call Transcript
LivaNova PLC (LIVN) Q3 2026 Earnings Call Transcript
Seeking Alpha • Nov 4, 2026

LivaNova Reports Third-Quarter 2026 Results; Raises Full-Year 2026 Revenue and Adjusted Diluted EPS Guidance
GLOUCESTER, England--(BUSINESS WIRE)---- $LIVN #OSA--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today reported results for the third quarter ended September 30, 2026 and raised full-year 2026 guidance. Financial Summary and Highlights(1) Third-quarter revenue of $393.1 million increased 9.9% on a reported basis and 10.0% on a constant-currency basis as compared to the prior-year period Third-quarter U.S. GAAP diluted earnings per share of $0.11 and adjusted diluted earnings per.
Business Wire • Nov 4, 2026

LivaNova (LIVN) Surpasses Q3 Earnings and Revenue Estimates
LivaNova (LIVN) came out with quarterly earnings of $1.23 per share, beating the Zacks Consensus Estimate of $1.03 per share. This compares to earnings of $1.11 per share a year ago.
Zacks Investment Research • Nov 4, 2026

LivaNova (LIVN) Reports Q3 Earnings: What Key Metrics Have to Say
The headline numbers for LivaNova (LIVN) give insight into how the company performed in the quarter ended September 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Zacks Investment Research • Nov 4, 2026

Neuromodulation Publishes Full 36-Month CORE-VNS Results Demonstrating Sustained and Increasing Benefits of LivaNova's VNS Therapy for Drug-Resistant Epilepsy
GLOUCESTER, England--(BUSINESS WIRE)---- $LIVN #OSA--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced that the journal Neuromodulation: Technology at the Neural Interface has published the full 36-month results from the CORE-VNS study, the first long-term effectiveness evaluation of contemporary VNS Therapy™ devices in people with Drug-Resistant Epilepsy (DRE). The article, “CORE-VNS Seizure and Non-Seizure 36 Month Outcomes in People with Drug-resistant Epilepsy,”1 re.
Business Wire • Oct 23, 2026

LivaNova to Present at UBS, Wolfe, Stifel, and Jefferies Healthcare Conferences in November
GLOUCESTER, England--(BUSINESS WIRE)---- $LIVN #OSA--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced that members of the Company's Executive Leadership Team will provide general business updates during fireside chats at the four following November healthcare conferences: UBS Global Healthcare Conference on Mon., Nov. 9, from 11-11:35 a.m. EST in Palm Beach, Fla. 8th Annual Wolfe Research Healthcare Conference on Tues., Nov. 10, from 9:20-9:50 a.m. EST in New York City.
Business Wire • Oct 21, 2026

LivaNova to Announce Third-Quarter 2026 Results
GLOUCESTER, England--(BUSINESS WIRE)---- $LIVN #OSA--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, will host a conference call to discuss its third-quarter 2026 results on Wed., Nov. 4, 2026, at 1 p.m. Greenwich Mean Time (8 a.m. Eastern Standard Time). The Company will release its third-quarter 2026 results prior to the call.The audiocast will be accessible at www.livanova.com/events. Listeners should log on approximately 10 minutes in advance to ensure proper setup to receive the.
Business Wire • Sep 23, 2026

¹ Disclosures

Open an M1 investment account to buy and sell LivaNova PLC commission-free¹. Build wealth for the long term using automated trading and transfers.